Researchers have identified gender inequality as a key factor driving the AIDS pandemic. Policymakers have called for sexuality and HIV education that emphasizes gender equality and human rights. Educators want to teach young people the critical thinking skills needed to build compassionate and just societies. It's All One Curriculum responds to these calls.

Cultural stigmas leave many young people in Tanzania in the dark about their sexual and reproductive health and rights. Our Member Association - Chama cha Uzazi na Malezi Bora Tanzania (UMATI) - has come up with a solution at their youth center in Dar es Salaam: peer-to-peer educators.  Every week over 100 youth sign up for services and training at the center. In 2017 the Global Gag Rule pulled funding from UMATI, however, the Belgian Government stepped in with emergency funding which allowed the center to remain open through the She Decides project.

"Disabled people are sexy" "If you’re blind, how do you have sex? And I’m thinking, what kind of sex are you having?" Our new series tackles five major topics: Sex & Disability, Sex & Pleasure, Sex & Consent, Sex Education and Sex & Social Media. In this episode, Joy and Rachelle talk about their own experiences of living with a disability and some of the stigma and stereotypes they face when it comes to sex. They also have a few handy tips (hint more people should have sex with people living with a disability) on how to incorporate your disability into your sex life!

The body of evidence on possible increased risk of HIV acquisition with use of progestogen‑only contraception has remained mixed since 1991, with the greatest concern of an increased risk of HIV acquisition centred on the use of intramuscular depot‑medroxyprogesterone acetate (DMPA‑IM). Data on the risk of HIV acquisition and use of other highly effective contraceptives such as norethisterone enanthate (NET‑EN), hormonal implants, and hormonal and non‑hormonal IUDs are limited.2 And there are no data on subcutaneous DMPA (DMPA‑SC) and HIV risk.  In 2016, an updated systematic review of epidemiological evidence on hormonal contraception and HIV acquisition concluded that there was a significant association between the use of DMPA and HIV acquisition and no increased HIV risk with oral contraceptive pills.3 The updated systematic review provided important data regarding DMPA users at high risk of HIV; however, confounding in these observational data could not be excluded. The historically mixed data and the need to control for confounding required further investigation into the association between use of progestogen‑only injectables and increased risk of HIV acquisition, using a more robust research design. This led to the development of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial.  

Universal health coverage means ensuring every person has access to quality, affordable health services and plays a pivotal role in achieving global development targets. Healthy populations can better contribute socially and economically, while poor health is a major driver of poverty. Universal access to sexual and reproductive health care services is identified in the Sustainable Development Goals as an essential contributor to ensuring healthy lives and promoting well-being for all at all ages. IPPF, together with the London School of Hygiene and Tropical Medicine, undertook a literature review looking at progress to date in and challenges to achieving universal access to sexual and reproductive health and rights. The review, Leaving no one behind, is illustrated with case studies on Afghanistan, Cambodia, Kenya and Sudan. Supported by the Japan Trust Fund.

In May 2018, the World Health Organization (WHO) reported a potential safety issue concerning dolutegravir (DTG), a common first-line antiretroviral treatment drug that is used to prevent and treat HIV infections. Preliminary findings from a study in Botswana found an increased risk of neural tube defects in infants born to women taking DTG at the time of conception. As a result of this study, WHO’s revised guidance on antiretroviral regimens for treating and preventing HIV infections, released in July 2018, include a caution on use of DTG by women and adolescent girls of childbearing potential. This brief aims to provide an overview of the research to date, current WHO guidance, and recommendations for IPPF.